Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

Inclusion Criteria: * Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including all clinical subtypes (primary mediastinal, intravascular, etc…), with all age-adjusted International Prognostic Index (aaIPI). May also be included: De Novo transformed DLBCL from low grade lymphoma (Follicular, other...) and DLBCL associated with some small cell Infiltration in bone marrow or lymph node; or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma; or CD20+ Follicular lymphoma grade 3B (according to WHO classification); or CD20+ Aggressive B-cell lymphoma unclassifiable. * With a Cluster of Differentiation antigen 10 (CD10) immunostaining performed by the participating center pathologist * Aged ≥ 80 years old * Ann Arbor stage II, III or IV * Patient previously untreated for DLBCL Lymphoma * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * With a minimum life expectancy of 3 months * Negative HIV, HBV and HCV serologies test within 4 weeks before inclusion (except after hepatitis B vaccination or for patients who are HBs Ag negative, anti-HBs positive and/or anti-HBc positive but viral DNA negative) * Patient able to give his consent and having signed a written Informed consent * Patient affiliated to social security system, if applicable * Male patients must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for 3 months following study drug discontinuation, even if they have undergone a successful vasectomy. * All patients must agree to fulfill the global Lenalidomide Pregnancy Prevention Risk Management Plan as applicable according to the randomization arm (randomization arm) Exclusion Criteria: * Any other histological type of lymphoma, Burkitt included * Any history of treated or non-treated small-B cell lymphoma * Central nervous system or meningeal involvement by lymphoma * Contra-indication to any drug contained in the chemotherapy regimens ; for anthracycline use, ejection fraction should be \> 50% * Any serious active disease (according to the investigator's decision) * History of deep venous thrombosis or arterial thromboembolism events within the past 12 months before inclusion * Poor renal function (creatinine clearance \< 40 ml/min, according to Modification of Diet in Renal Disease (MDRD) formula) * Poor hepatic function (total bilirubin level \>30mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma * Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration * Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma Patients previously diagnosed with prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason score ≤7, and a prostate specific antigen (PSA) ≤10 ng/mL prior to initial therapy, (2) they had definitive curative therapy (i.e., prostatectomy or radiotherapy) 2 years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they had no clinical evidence of prostate cancer, and their PSA was undetectable if they underwent prostatectomy or \<1 ng/mL if they did not undergo prostatectomy * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study * Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy * Prior use of lenalidomide * Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide * Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide * Subjects with ≥ Grade 2 neuropathy * Adult patient under tutelage * Female of childbearing potential are excluded. (Note: Females are defined as not of childbearing potential if there is documentation of "natural menopause for at least 24 consecutive months, a hysterectomy or bilateral oophorectomy")